Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Dr. Gillis' Wellness Center vs Kin Meds

Dr. Gillis' Wellness Center
Graded #169

Lower grade

vs+5.900000000000006
Kin Meds
Graded #73

Higher grade

The verdict

Kin Meds takes it — 72.9/100 to 67/100.

Kin Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Kin Meds is a LegitScript-verified telehealth platform offering both compounded GLP-1s (semaglutide from $199/mo, tirzepatide from $249/mo) and brand-name FDA-approved options including Wegovy injection and…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueKin Meds +10
64
74
Dose & formulationKin Meds +25
68
93
Clinical oversightDr. Gillis' Wellness Center +10
84
74
Labs & monitoringEven
53
53
FulfillmentDr. Gillis' Wellness Center +9
81
72
Contract termsKin Meds +18
37
55
Dr. Gillis' Wellness Center · left barKin Meds · right bar

The numbers

MetricDr. Gillis' Wellness CenterKin Meds
WeighScore67/10072.9/100
GradeCC
Scorecard rank#169#73
Semaglutide$149/mo (starting dose, compounded)$149/mo (brand Wegovy)
TirzepatideNot disclosed$149/mo (brand Zepbound)
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualYesYes

Strengths

  • Sublingual ODT tablets offered as needle-free alternative
  • Broad GLP-1 menu: semaglutide, tirzepatide, and retatrutide
  • Transparent pricing: $150 starting dose, plans from $149/mo
  • Led by board-certified physician/surgeon with 25+ years experience
  • No contracts; flexible weekly, bi-weekly, or monthly cadence

Where it loses points

  • Specific dose-tier pricing beyond starting plan not detailed
  • Compounded vs brand not explicitly stated for all meds
  • Smaller clinic vs national telehealth brands
  • State licensing list not published
Kin Meds

Graded #73 · C

Strengths

  • Publicly lists $199/mo compounded semaglutide and $249/mo compounded tirzepatide
  • Brand-name options too — Wegovy injection and pill, Zepbound, Foundayo from $149/mo entry pricing
  • LegitScript verified
  • Clearly identifies itself as the intake platform and a licensed third-party pharmacy as the dispenser
  • Broad longevity menu (Sermorelin, NAD+, Glutathione) plus TRT, hair, skin, and sexual health

Where it loses points

  • Legal entity name and state of incorporation not publicly disclosed
  • The third-party pharmacy partner isn't named, and Kin Meds isn't itself a licensed pharmacy
  • Per-state availability not listed
  • $149/mo brand pricing is the insured entry tier — cash-pay patients should expect higher real costs
  • Lab work and dose-titration support not clearly described

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard